425 results on '"Michot, J."'
Search Results
2. Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases
3. Médicaments utilisés dans la prise en charge de l’infection à SARS-CoV-2 : étude rétrospective des principales associations à risque d’interactions médicamenteuses et des effets indésirables médicamenteux
4. Toxicités immunologiques induites par les inhibiteurs de checkpoint en 2019 : mise au point
5. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.
6. Ulcères de jambes développés sous inhibiteurs de tyrosine kinase ciblant le récepteur du VEGF
7. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
8. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA
9. Place de la radiothérapie dans la prise en charge des lymphomes NK/T de type nasal et primitifs cérébraux
10. 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
11. 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
12. 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study
13. 508P High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors
14. 657P Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
15. 469P Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
16. Le syndrome d’activation lymphohistiocytaire de l’adulte
17. Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors
18. From hepatitis C virus infection to B-cell lymphoma
19. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
20. S216: CLINICAL ACTIVITY OF CC-99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (R/R NHL) – RESULTS FROM A PHASE 1, OPEN-LABEL STUDY
21. PB2102: PHASE 2 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PLAMOTAMAB COMBINED WITH TAFASITAMAB (TAFA) + LENALIDOMIDE (LEN) VS TAFA+LEN IN RELAPSED OR REFRACTORY DLBCL
22. S217: PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.
23. 193P Safety and efficacy of immmunotherapy rechallenge following a previous immune-induced interstitial lung disease
24. P315 Gastrointestinal immune related adverse events associated with programmed-Death 1 blockade
25. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
26. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
27. L’utilisation de Rituximab chez le sujet âgé pour une maladie auto immune est à risque accru d’infection opportuniste
28. Molecular and Cytogenetic Evidence for the Location of Tdy and Hya on the Mouse Y Chromosome Short Arm
29. 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
30. 1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy
31. 1773P Anti-PD1-induced acute interstitial pneumonitis is characterized by alveolar infiltration of PD-1+CD38+TIGIT+ cytotoxic effector CD8+ T cells and CD206+ inflammatory macrophages
32. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
33. A PHASE 1, MULTICENTER, OPEN‐LABEL STUDY OF CC‐99282 ALONE AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS
34. 1845P Exclusion of patients with psychiatric disorders from early phase oncology trials: A limited access to innovation?
35. 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
36. 516P Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
37. 2158P A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
38. OPEN‐LABEL PHASE 1/2 STUDY OF CC‐99282, A CEREBLON E3 LIGASE MODULATOR (CELMOD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL).
39. 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis
40. 9P Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials
41. 8MO CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
42. Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency
43. 47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs
44. 66P High incidence of TP53 and epigenetic modifying oncogene mutations in a large cohort of patients enrolled in phase I clinical trials for R/R DLBCL
45. 24P Is molecular characterization useful for targeted therapy orientation in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) included in early phase clinical trials?
46. 1050P Does immunotherapy impact the outcomes of future anti-tumour therapies?
47. 1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy
48. 527O CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study
49. 16O Phase I study of CC-90010, a reversible, oral BET inhibitor in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
50. Quinolones in 2005: an update
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.